angiotensin i/ii

Angiotensin I/II (1-6) TFA is a chemical compound comprising amino acids 1-6, derived from the Angiotensin I/II peptide. This peptide is formed by the cleavage of angiotensinogen by renin, with Angiotensin I subsequently hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].

Angiotensin I/II (1-5) is a peptide (ASP-ARG-VAL-TYR-ILE) that contains the amino acids 1-5 and is converted from Angiotensin I/II.

Angiotensin I/II (1-6) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS) that contains the amino acids 1-6 and is converted from Angiotensin I/II peptide.

Angiotensin III is an agonist of angiotensin 1 (AT1) and AT2 receptor.

Angiotensin III TFA is an agonist of angiotensin 1 (AT1) and AT2 receptor.

Angiotensin III, human, mouse (Angiotensin III, human, mouse(3TFA))(3TFA) is an endogenous angiotensin II receptor (AT2R) agonist(IC50s of 0.648 nM).

Angiotensin III, human, mouse (TFA), is a peptide hormone involved in blood pressure regulation.

[Val4] Angiotensin III is an angiotensin III peptide variant and a potent full agonist for Gαq and βarr2 signaling pathways, with pEC50 values of 8.31 and 8.44, respectively [1].

Angiotensin Iii(Ile* U-13C6,15N) (Standard) is a reference standard of Angiotensin Iii(Ile* U-13C6,15N) intended for quantitative analysis, quality control, and related biochemical research applications.

Angiotensin III, human is a polypeptide molecule with the sequence RVYIHPF.

Losartan potassium (DuP-753 potassium), an Angiotensin II Receptor Blocker, selectively and competitively inhibits the binding of angiotensin II to the angiotensin I (AT1) receptor.

Captopril (SA333) is a potent and specific inhibitor of peptidyl-dipeptidase A. It blocks the conversion of angiotensin I to angiotensin II, a vasoconstrictor and important regulator of arterial blood pressure.

Perindopril erbumine (S9490-3) is the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, Perindopril erbumine (S9490-3) is converted to its active form perindoprilat, inhibiting ACE and the conversion of angiotensin I to angiotensin II; consequently, angiotensin II-mediated vasoconstriction and angiotensin II-stimulated aldosterone secretion from the adrenal cortex are inhibited and diuresis and natriuresis ensue.

Olmesartan (RNH 6270) is an Angiotensin II Type I receptor antagonist. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil,and has antihypertensive activity.

UR-7247 is a novel orally active angiotensin II subtype I (AT1) antagonist, demonstrating very long pharmacological effects. in vivo studies indicate no significant difference between 10 mg UR-7247 and 100 mg losartan four hours post-administration, while in vitro blockade with 100 mg losartan exceeds that observed with UR-7247, confirming UR-7247’s extended plasma half-life potentially due to high-affinity protein binding, highlighting its long-lasting, well-tolerated AT1 receptor antagonism in healthy subjects.

Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. It selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor.

Pivalopril, a novel orally active angiotensin-converting enzyme inhibitor, acts by blocking the conversion of angiotensin I to angiotensin II.

PD 109488 is a metabolite of quinapril and is a derivative of Quinapril that acts as an ACE inhibitor. Inhibition of ACE prevents the conversion of signaling peptide angiotensin I into angiotensin II, which acts as a potent vasoconstrictor. Reduced levels of angiotensin II also reduces the amount of aldosterone that is expressed due to RAAS signaling.

Angiotensin I-13C6,15N (human, mouse, rat) trifluoroacetic acid is a labeled version of Angiotensin I, using isotopes 13C and 15N, specifically targeted for human, mouse, and rat studies. This compound serves as a precursor to angiotensin II, which is formed through the cleavage by angiotensin-converting enzyme (ACE).

Quinapril is an orally active, non-peptide, and non-thiol angiotensin-converting enzyme (ACE) inhibitor. It primarily blocks the conversion of angiotensin I to angiotensin II in both plasma and tissues. Upon enzymatic hydrolysis, Quinapril is converted into the pharmacologically active Quinaprilat and is effective in hypertension models.

Quinaprilat is an orally active ACE inhibitor, the active metabolite of quinapril, and a substrate for OAT3. It blocks the conversion of angiotensin I to angiotensin II, exhibiting antihypertensive activity.

Fructose-phenylalanine (Fru-Phe) is a non-competitive inhibitor of angiotensin-converting enzyme (ACE) with an IC50 of 0.19 mM, exhibiting antioxidant properties. It forms a stable complex with zinc ions (Zn2+) at the active site of ACE, effectively inhibiting the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure. Fructose-phenylalanine shows potential for research in cardiovascular diseases.

Angiotensin I/II (1-7) amide is a peptide analog to angiotensin II that is used as a vasopressor in the treatment of certain types of shock and circulatory collapse. Angiotensin I/II amide is an amide derivative of angiotensin II that is a powerful vasoco

Angiotensin I/II (2-7) is a peptide that contains the amino acids 2-7 and is converted from Angiotensin I/II peptide. Angiotensin is a peptide hormone that causes vasoconstriction and a subsequent increase in blood pressure. Angiotensin also stimulates th